- Home
- INVE vs PYXS Comparison
INVE vs PYXS Comparison
Compare INVE & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVE
- PYXS
- Stock Information
- Founded
- INVE 1990
- PYXS 2018
- Country
- INVE United States
- PYXS United States
- Employees
- INVE N/A
- PYXS N/A
- Industry
- INVE Computer peripheral equipment
- PYXS Biotechnology: Pharmaceutical Preparations
- Sector
- INVE Technology
- PYXS Health Care
- Exchange
- INVE Nasdaq
- PYXS Nasdaq
- Market Cap
- INVE 85.9M
- PYXS 79.4M
- IPO Year
- INVE 1997
- PYXS 2021
- Fundamental
- Price
- INVE $3.79
- PYXS $3.91
- Analyst Decision
- INVE Strong Buy
- PYXS Strong Buy
- Analyst Count
- INVE 2
- PYXS 5
- Target Price
- INVE $5.50
- PYXS $8.25
- AVG Volume (30 Days)
- INVE 36.3K
- PYXS 917.8K
- Earning Date
- INVE 11-10-2025
- PYXS 11-03-2025
- Dividend Yield
- INVE N/A
- PYXS N/A
- EPS Growth
- INVE N/A
- PYXS N/A
- EPS
- INVE 3.12
- PYXS N/A
- Revenue
- INVE $23,538,000.00
- PYXS $2,820,000.00
- Revenue This Year
- INVE N/A
- PYXS N/A
- Revenue Next Year
- INVE $9.06
- PYXS N/A
- P/E Ratio
- INVE $1.22
- PYXS N/A
- Revenue Growth
- INVE N/A
- PYXS N/A
- 52 Week Low
- INVE $2.86
- PYXS $0.83
- 52 Week High
- INVE $4.29
- PYXS $5.39
- Technical
- Relative Strength Index (RSI)
- INVE 50.32
- PYXS 69.03
- Support Level
- INVE $3.71
- PYXS $3.17
- Resistance Level
- INVE $4.07
- PYXS $4.17
- Average True Range (ATR)
- INVE 0.21
- PYXS 0.31
- MACD
- INVE -0.01
- PYXS -0.01
- Stochastic Oscillator
- INVE 50.38
- PYXS 74.07
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.